Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COLONYVAQ-CRC + mFOLFOX6 + CAPOX + nivolumab
- Development stage
- Unknown
- Lead developer
- Biogenea
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
COLONYVAQ-CRC is a personalized, multi-peptide neoantigen vaccine developed by Biogenea Pharmaceuticals Ltd. using a physics-aware, quantum-classical AI-guided pipeline. The vaccine consists of up to 20 patient-specific synthetic peptides (8-30 amino acids) selected based on tumor/normal whole-exome and RNA sequencing to stimulate a T-cell response against tumor-specific neoantigens. In this therapeutic regimen, COLONYVAQ-CRC is administered in combination with standard adjuvant oxaliplatin-based chemotherapy (either mFOLFOX6 or CAPOX) and the immune checkpoint inhibitor nivolumab. This combination is being investigated for the treatment of patients with completely resected stage III microsatellite-stable (MSS) or proficient mismatch repair (pMMR) colorectal cancer. The regimen aims to enhance the immune system's ability to recognize and eliminate residual cancer cells, thereby preventing disease recurrence.
- Other names
- COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab
02
Targets
DNAMHC II (Major histocompatibility complex class II receptor)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)Neoantigen-specific T-cell receptor
Beyond the preview
Go deeper on COLONYVAQ-CRC + mFOLFOX6 + CAPOX + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COLONYVAQ-CRC + mFOLFOX6 + CAPOX + nivolumab.